Page last updated: 2024-11-05

triazolam and Sleep Apnea, Obstructive

triazolam has been researched along with Sleep Apnea, Obstructive in 1 studies

Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Weaver, JM1

Other Studies

1 other study available for triazolam and Sleep Apnea, Obstructive

ArticleYear
When can a normal dose be an overdose? Who is at risk?
    Anesthesia progress, 2014,Summer, Volume: 61, Issue:2

    Topics: Adjuvants, Anesthesia; Age Factors; Anesthetics, Local; Conscious Sedation; Dose-Response Relationsh

2014